Kezar Life Sciences (NASDAQ:KZR) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapies that modulate the innate immune system. The company’s research centers on selective inhibition of the immunoproteasome, a key protein complex involved in antigen processing and secretion of inflammatory cytokines. By targeting this pathway, Kezar aims to address unmet medical needs in autoimmune and inflammatory diseases with high specificity and a favorable safety profile.
The company’s lead development candidate, KZR-616, is a selective immunoproteasome inhibitor being evaluated in multiple clinical trials for autoimmune conditions such as systemic lupus erythematosus, lupus nephritis, polymyositis and dermatomyositis. Early clinical data have demonstrated reductions in inflammatory biomarkers and improvements in disease activity scores. Kezar’s pipeline also includes preclinical programs exploring complementary immunoproteasome and innate immune targets, with the goal of expanding treatment options across a range of inflammatory disorders.
Founded in 2015 and headquartered in South San Francisco, Kezar Life Sciences was established with venture backing to advance precision immunology research. The company operates under the leadership of CEO Heather Franklin, whose prior experience spans oncology and immunology drug development. Kezar’s management team combines expertise in medicinal chemistry, immunology, and clinical development to drive its product candidates through late-stage studies.
Kezar Life Sciences conducts its clinical trials primarily within the United States, with additional study sites in Europe and Asia through strategic collaborations. The company maintains partnerships with academic research centers and industry organizations to facilitate patient enrollment, assay development and biomarker analysis, positioning Kezar to deliver targeted therapies to patients globally.
